摘要
目的:儿茶酚抑素(catestatin)是一种新发现的具有抑制儿茶酚胺释放作用的内源性神经肽,该文拟探讨血浆儿茶酚抑素在心力衰竭患者中的变化及可能的病理生理意义。方法:入选45例心力衰竭患者及30例健康对照组,采用酶联免疫分析法测定血浆儿茶酚抑素,高效液相色谱分析法测定血浆去甲肾上腺素浓度。结果:与健康对照组相比,心衰患者血浆儿茶酚抑素(0.88±0.30 vs 0.41±0.14 ng/ml)及去甲肾上腺素(421.9±61.4vs 210.2±55.4 pg/ml)显著升高(P<0.01);治疗后均明显降低(P<0.01),但未降至健康对照组水平;治疗后儿茶酚抑素/去甲肾上腺素的比值较前显著升高(2.39±0.70 vs 1.95±0.64,P<0.01)。不同NYHA分级的心衰患者间及射血分数正常和降低的心衰患者间血浆儿茶酚抑素没有显著性差异。儿茶酚抑素与左室射血分数、超敏C反应蛋白、肌钙蛋白I无明显相关(P>0.05),但与氨基末端前脑钠肽存在正相关(r=0.38,P<0.05)。儿茶酚抑素诊断心力衰竭的ROC曲线下面积为0.94。结论:心力衰竭患者血浆中的儿茶酚抑素升高,与NTproBNP呈正相关,儿茶酚抑素有可能成为心力衰竭新的生化标志物。
Objective Catestatin is a newly discovered endogenous neuropeptide with potent catecholamine release-inhibitory activity.The purpose of the present study was to evaluate the possible pathophysiologic role of catestatin through investigation of plasma catestatin levels in patients with congestive heart failure（CHF）.Methods Plasma catestatin was measured with enzyme-linked immunosorbent assay and norepinephine was measured with high performance liquid chromatography in 45 patients with CHF and 30 controls.Results Plasma catestatin（0.88±0.30 vs 0.41±0.14 ng/ml） and norepinephrine（421.9±61.4 vs 210.2±55.4 pg/ml） levels were significantly higher in patients with CHF than those in controls（P〈0.01）.Both neuroendocrine factors levels decreased after treatment,but still remained significantly higher than those in controls（P〈0.01）.However,in CHF patients after treatment,the catestatin/norepinephrine ratio was significantly increased（2.39±0.70 vs 1.95±0.64,P〈0.01）.Plasma catestatin levels were similar among patients with different NYHA classes,as well as between patients with normal and reduced ejection fraction.Plasma catestatin level was correlated positively with NTproBNP level（r=0.38,P〈0.05）,while no correlation was found between catestatin and left ventricular ejection fraction,hsCRP or cTNI.The area under ROC curve of catestatin in CHF for diagnosis was 0.94.Conclusion Plasma catestatin levels in patients with CHF were significantly elevated and positively correlated with NTproBNP.Catestatin might be used as a new biomarker in CHF.
出处
《放射免疫学杂志》
CAS
2009年第4期393-396,共4页
Journal of Radioimmanology
关键词
儿茶酚抑素
心力衰竭
catestatin congestive heart failure
